## Atty. Docket No. PI4749Usw

whichever occurs first.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	IN THE UNITED STATES I	AIEMI AMD INADA	MARKE OFFICE							
IN RE: Ap	oplication of Alvaro et al.		; ;							
Serial No.:	10/502,266	Art Unit: 1614	,							
Filing Date	e: March 17, 2005	Examiner: To be Assig	gned '							
	PERIDYLCARBOXAMIDE DERIVATI NN-MEDIATED DISEASES	VES AND THEIR USE IN 1	HE TREATMENT OF							
P.O. Box 1	1450									
	SUPPLEMENTAL INFORM	AATION DISCLOSURI	E STATEMENT							
months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).  OR										
A. []	months of the filing date of the of an international application	e above application or dat or before the mailing dat	e of entry into the national stage							
[]	The Information Disclosure mailing of a first office action Examination under 37 C.F.R.	n after the filing of a Re	quest For Continued							
B. [X]	The Information Disclosure Staten of the filing date of the above app forth in § 1.491 of an international Action on the merits, whichever ev (1) a final action under § 1.11	lication or the date of ent application or after the r yent occurred last, but be 3 or	ry into the national stage as set nailing date of the first Office							

## Atty. Docket No. PI4749Usw

- [ ] Applicant hereby certifies that each item of information contained in this Information
  Disclosure Statement was cited in a communication from a foreign patent office in a
  counterpart foreign application not more than three months prior to the filing of this
  statement.
- [X] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [ ] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[ ] A duplicate copy of this paper is attached.

Respectfully Submitted

Lorie Ann Morgan Attorney of Record Registration No. 38,181

Date: 23 Aug. 2006 Customer No. 23347

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222 Facsimile: (919) 483-7988

								St	neet <u>1</u> of <u>1</u>		
Form PTO-1449 U.S. Department of Co Patent and Tradema		rtment of Commer	ce ice	ATTY DOCKET NO. PI4749USW	SERIAL NO. 10/502,268						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Alvaro et el.							
				FILING DATE GROUP March 17. 2005 1614							
			U.S. PA	TEN	IT DOCUMENTS						
Examiner Initiels		Document Number Data			Name	Class	Subclass	Filing Date If Appropriate			
							<u> </u>				
			-	-	<u>.                                      </u>	-	···· ,				
		<del>                                     </del>	<del>                                     </del>			_	<del> </del>				
						i					
-											
	<u> </u>	L	l			l					
				PA	TENT DOCUMENTS		la i di i				
		Document Number	Date		Country	Class	Subclass	1 ra Yes	nslation No		
	1	WO-03 099787-A1	12 -04 -2003 W	φ.					×		
						_					
	<del> </del>										
	-	<u> </u>									
			<del>                                     </del>				,				
	1	OTHER D	OCUMENTS (Include	ling .	Author, Title, Date, Pertinent I	Pages, Etc)					
•											
	ļ		4.6.19								
	<u> </u>										
			•								
Examiner Signature				Da	ate Considered ,						
EXAMINER: not consider	initial if refe ed. include	erence considered, who copy of this form with	nether or not citation is in next communication to a	appi	nformance with MPEP 609. Draw line	ne through ci	tation if not	in conform	nance and		